OMDA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

8 Analyst Rating

Wall Street analysts forecast OMDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMDA is 28.50 USD with a low forecast of 24.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

1 Hold

0 Sell

Strong Buy

Current: 14.610

Low

24.00

Averages

28.50

High

32.00

Current: 14.610

Low

24.00

Averages

28.50

High

32.00

BMO Capital

Outperform

initiated

$27

2025-11-12

Reason

BMO Capital

Price Target

$27

2025-11-12

initiated

Outperform

Reason

BMO Capital initiated coverage of Omada Health with an Outperform rating and $27 price target. A large under-penetrated total addressable market, recent roll-out of an enhanced GLP-1 companion program, AI investments, and increasing cross-selling momentum provides significant runway for continued revenue growth of 20%+ and expanding margins, the analyst tells investors in a research note.

Evercore ISI

Outperform

maintain

$27 -> $28

2025-11-07

Reason

Evercore ISI

Price Target

$27 -> $28

2025-11-07

maintain

Outperform

Reason

Evercore ISI raised the firm's price target on Omada Health to $28 from $27 and keeps an Outperform rating on the shares after Q3 revenue and EBITDA beat expectations and FY25 guidance was raised.

Morgan Stanley

Overweight

maintain

$30 -> $32

2025-11-07

Reason

Morgan Stanley

Price Target

$30 -> $32

2025-11-07

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on Omada Health to $32 from $30 and keeps an Overweight rating on the shares. Q3 revenue increased 49% year-over-year and beat by 11%, and the company crossed the threshold to EBITDA profitability, the analyst tells investors in a research note. The firm added that momentum continues, and the big development on the quarterly call was expanding its GLP-1 offering to include prescribing.

Barclays

Saket Kalia

Overweight

maintain

$28 -> $29

2025-11-07

Reason

Barclays

Saket Kalia

Price Target

$28 -> $29

2025-11-07

maintain

Overweight

Reason

Barclays analyst Saket Kalia raised the firm's price target on Omada Health to $29 from $28 and keeps an Overweight rating on the shares. The company reported "another beat and raise" quarter, the analyst tells investors in a research note.

Barclays

Overweight

maintain

$24 -> $28

2025-10-22

Reason

Barclays

Price Target

$24 -> $28

2025-10-22

maintain

Overweight

Reason

Barclays raised the firm's price target on Omada Health to $28 from $24 and keeps an Overweight rating on the shares ahead of the earnings report on November 6. The firm expects another "beat and raise" quarter based on seasonal trends, adoption of the company's higher priced programs, growing GLP-1 use.

Baird

Neutral

initiated

$24

2025-09-05

Reason

Baird

Price Target

$24

2025-09-05

initiated

Neutral

Reason

Baird last night initiated coverage of Omada Health with a Neutral rating and $24 price target. The company's platform addresses important chronic conditions that have wide prevalence across the population, the analyst tells investors in a research note. However, Baird views the uncertain macro backdrop, Omada's relatively high customer concentration, and its limited profitability as creating heightened risk for the shares.

Valuation Metrics

The current forward P/E ratio for Omada Health Inc (OMDA.O) is -43.83, compared to its 5-year average forward P/E of -139.19. For a more detailed relative valuation and DCF analysis to assess Omada Health Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-139.19

Current PE

-43.83

Overvalued PE

328.97

Undervalued PE

-607.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

244.66

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

798.65

Undervalued EV/EBITDA

-309.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.18

Current PS

0.00

Overvalued PS

5.20

Undervalued PS

3.15

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

OMDA News & Events

Events Timeline

No data

News

2.0

11-20NASDAQ.COM

Omada Health (OMDA) Experiences Oversold Conditions

1.0

11-20Newsfilter

Omada Health to Attend Evercore Healthcare Conference

6.0

11-07Benzinga

Evercore ISI Group Keeps Outperform Rating for Omada Health and Increases Price Target to $28

People Also Watch

Frequently Asked Questions

What is Omada Health Inc (OMDA) stock price today?

The current price of OMDA is 14.61 USD — it has increased 0.14 % in the last trading day.

What is Omada Health Inc (OMDA)'s business?

Omada Health Inc. is a virtual-first healthcare provider that nurtures lifelong health. The Company has one operating segment, namely all virtual care program product offerings. The Company’s member-facing platform is designed to offer an integrated experience that encompasses the full range of direct interactions. It offers range of programs like Omada for Prevention & Weight Health, Omada for Diabetes, Omada for Hypertension, Omada for musculoskeletal (MSK), and Omada GLP-1 Care Tracks. Its Omada for Prevention & Weight Health programs focus on prediabetes and weight management, two critical elements of preventing diabetes and heart disease. Its Omada for Diabetes program is designed to help members with type 1 or type 2 diabetes achieve stable blood glucose levels and meet and reach their goals for reducing hemoglobin A1C. Its Omada for Hypertension is designed to help reduce members blood pressure and help them maintain healthy blood pressure.

What is the price predicton of OMDA Stock?

What is Omada Health Inc (OMDA)'s revenue for the last quarter?

Omada Health Inc revenue for the last quarter amounts to 68.03M USD, increased 49.47 % YoY.

What is Omada Health Inc (OMDA)'s earnings per share (EPS) for the last quarter?

Omada Health Inc. EPS for the last quarter amounts to -0.06 USD, decreased -64.71 % YoY.

What changes have occurred in the market's expectations for Omada Health Inc (OMDA)'s fundamentals?

The market is revising Upward the revenue expectations for Omada Health, Inc. (OMDA) for FY2025, with the revenue forecasts being adjusted by 6.07% over the past three months. During the same period, the stock price has changed by -35.15%.

How many employees does Omada Health Inc (OMDA). have?

Omada Health Inc (OMDA) has 849 emplpoyees as of December 17 2025.

What is Omada Health Inc (OMDA) market cap?

Today OMDA has the market capitalization of 846.04M USD.